SlideShare una empresa de Scribd logo
1 de 25
Descargar para leer sin conexión
Post-Marketing Compliance
            &
Health Canada Progressive
        Licensing

    Professor Peivand Pirouzi
              2006

  FDA/Health Canada Guidances
Reporting Adverse Events for Drugs, Devices,
          Biologics and Dietary Supplements
 FDA's Medwatch program allows health care professionals and consumers to report to the FDA
  serious problems with the medical products they prescribe, dispense, or use. These reports,
  along with follow-up investigations, can help to identify important safety concerns.

   Take the example of the antibiotic Zyvox. Within the first six months of Zyvox's marketing, FDA
   began getting MedWatch reports of myelosupression from clinicians who suspected that the
   drug might be responsible. After investigating the problem, we worked with the manufacturer to
   change the Zyvox labeling to warn about the potential for myelosuppression.

   Sometimes MedWatch reports highlight errors in prescribing or administering medications. For
   example, FDA received reports of patient injuries due to name confusion between LANOXIN, a
   heart medication, and what used to be called LEVOXINE, a thyroid medication. As a result, FDA
   asked the manufacturer to change the name of Levoxine, and now it's known as LEVOXYL,
   which is less likely to be confused with LANOXIN.

   The MedWatch system can also help detect problems with medical products other than drugs.
   For example, FDA received two reports of pneumococcal eye infections in patients who'd
   received corneal transplants. An FDA inspection identified numerous manufacturing problems,
   which led the company to recall the implants.
Reporting Adverse Events for Drugs, Devices,
           Biologics and Dietary Supplements
   Of course, MedWatch reports by themselves can not usually establish a causal relationship between an adverse
    event and a medical product - it may take a formal epidemiologic study to do that. Still, MedWatch reports are vital
    in making sure that medical products are safe, because they provide a rapid signal to FDA that problems may be
    occurring.

    It is important to keep the MedWatch system working, and we can not do that without your help. Here are the kinds
    of reports we need from you:

    • First of all, we are asking that you report any serious adverse event that might be associated with a drug, biologic,
    medical device, or dietary supplement. By "serious" we mean fatalities, hospitalizations, and medically significant
    events. We're especially interested in serious adverse events that aren't listed in the product labelling.

    • Secondly, report therapeutic failures - cases where the drug or device failed to work as it should. For example, let
    us know if a patient has to switch from one brand of a drug to another because the original one was ineffective.

    • Third, tell us about cases of use errors with medications or devices, including situations where the error may have
    been due to poor communication, or to ambiguities in product names, directions for use, or packaging.

    • And finally, we would like to know about product quality issues, such as suspected counterfeit products, defective
    components, potential contamination, device malfunctions and poor packaging.
MedWatch: Reporting Adverse Events

1. FDA's Medwatch program allows health care professionals and consumers
   to report to the FDA serious problems with the medical products they
   prescribe, dispense, or use. These reports, along with follow-up
   investigations, can help to identify important safety concerns.

2. It is important to keep the MedWatch system working, and we can
   not do that without your help. Here are the kinds of reports we need
   from you:
    –   Report any serious adverse event that might be associated with a drug, biologic, medical device, or
        dietary supplement. By "serious" we mean fatalities, hospitalizations, and medically significant events.
        FDA is especially interested in serious adverse events that aren't listed in the product labeling.
    –   Report therapeutic failures - cases where the drug or device failed to work as it should (e.g., if a patient
        has to switch from one brand of a drug to another because the original one was ineffective).
    –   Report cases of use errors with medications or devices, including situations where the error may have
        been due to poor communication, or to ambiguities in product names, directions for use, or packaging.
    –   Report product quality issues, such as suspected counterfeit products, defective components, potential
        contamination, device malfunctions and poor packaging.
Stronger Risk Management Program for
              Accutane (isotretinoin)
 Isotretinoin is now a restricted distribution drug. This means that
  wholesalers won't be able to distribute the drug, pharmacists won't be able
  to dispense it, physicians won't be able to prescribe it, and patients won't be
  able to receive it unless they register. Doctors, patients, and pharmacies
  can obtain program information and register with iPLEDGE either online or
  by telephone at 1-866-495-0654.

   There is also a possible link between taking this drug and depression,
   suicidality, and psychosis. And for that reason, FDA has strengthened the
   labeling to help practitioners and patients identify and manage these risks.

   Any patient being treated with this drug should be carefully monitored for
   symptoms of depression, or suicidalility or psychosis. Patients should be
   told to stop the drug and contact their health professional if they experience
   any of these symptoms. Stopping the drug by itself, however, may not be
   sufficient. Psychiatric evaluation and intervention may be needed to prevent
   patients from harming themselves.
Stronger Risk Management Program for
               Accutane (isotretinoin)
 Revised October 28, 2005: The implementation dates of the iPLEDGE program have
  been revised. The date by which wholesalers and pharmacies must be registered
  /activated in IPLEDGE has been changed from November 1, 2005 to December 30,
  2005. By March 1, 2006, only prescribers registered and activated in iPLEDGE can
  prescribe isotretinoin and only patients registered and qualified in iPLEDGE can be
  dispensed isotretinoin. Patients can begin registering and qualifying on December 30,
  2005.

   FDA has developed stronger requirements to prevent fetal exposure to the drug
   Accutane (isotretinoin) along with its generic equivalents, such as Amnesteem, Sotret
   and Claravis. Isotretinoin is used to treat severe, recalcitrant, nodular acne, but it can
   cause serious birth defects if taken by pregnant women.

   These requirements are now going into effect in a new program called iPLEDGE.
   Under this program, wholesalers, prescribers, pharmacies and patients, both men
   and women, must register. Also, women who are capable of becoming pregnant must
   have two negative pregnancy tests before isotretinoin can be dispensed to them.
   They also must have a negative pregnancy test each month while taking the drug.
FDA Studying Potential Safety Issues
            with Several Drugs
 FDA has informed the health care community about ongoing safety
  reviews of several drugs. FDA is doing this as part of its commitment
  to inform health care professionals and the public about its ongoing
  drug safety reviews. Because this information is preliminary and
  there is scientific uncertainty, FDA is not taking regulatory action at
  this point, and is not advising health care professionals to stop using
  the drugs. FDA is continuing to evaluate the safety of these
  products, and will issue updates as more information becomes
  available.

• CellCept (mycophenolate mofetil) and Myfortic (mycophenolic acid)
 • Singulair (montelukast)
 • Spiriva Handihaler (tiotropium)

New Rule Enhances the Safety of Human
               Cells and Tissues
 FDA recently finalized a new rule that's designed to increase the safety of human
  cells, tissues and cellular and tissue-based products that are used for
  transplantation. The regulations apply to a broad range of products, including bone,
  ligaments, skin, corneas, and hematopoietic stem cells. They also apply to human
  heart valve and human dura mater allografts. The rule requires that manufacturers of
  these products recover, process, store, label, package and distribute them in a way
  that prevents the spread of communicable diseases.

   In this rule, FDA uses the word "manufacture" as an umbrella term to capture the
   many different actions an establishment might take in preparing these products for
   use. Many types of establishments may be involved in various steps from recovery,
   donor screening and testing, to storage and distribution. If an establishment is
   involved in any of the steps covered by the new regulation, FDA calls it a
   manufacturer.

   Prior to the new rule, there were some regulations in place to help assure the safety
   of human tissue. But the new rule covers a broader range of products and has more
   comprehensive requirements. This will help assure health care providers that the
   tissue and cellular products they use are the safest available.
Reporting Adverse Events from Vaccines

 Every year, tens of millions of vaccinations are given to children and adults in this
  country to prevent serious infectious diseases. FDA and CDC work together to
  monitor the safety of these vaccines using a registry known as Vaccine Adverse
  Event Reporting System, or VAERS. The VAERS registry contains reports of adverse
  events from patients, parents and health care providers, and it can help to identify
  important new vaccine safety concerns.

   Take the example of the rotavirus vaccine. During the first months after this vaccine
   was approved, epidemiologists at FDA and CDC noticed 15 VAERS reports of infants
   who had developed a particular type of intestinal obstruction after receiving the
   vaccine. The reports signaled a potential problem, which led to further investigations.
   As a result, the vaccination program was suspended, and then later, as
   investigations verified the serious risk, the manufacturer voluntarily removed the
   vaccine from the market.
Reporting Adverse Events from Vaccines
 Of course, it takes multiple reports and thorough investigation to confirm a causal
  relationship between an adverse event and a vaccine. Still, VAERS reports are on the
  front line in making sure that vaccines are safe, by providing a rapid signal that problems
  may be occurring.
   Sometimes VAERS reports highlight errors in prescribing or administering vaccines. For
   example, the VAERS registry was found to contain reports of 22 pregnant women who
   had received live virus varicella vaccine by mistake after being exposed to chickenpox.
   These women should have received a different product, varicella zoster immune globulin,
   or "VZIG."
   In this case, FDA and CDC worked with the varicella vaccine manufacturer to publish
   details about the 22 cases. By publishing this information, we were able to alert health
   care professionals of this potential mix-up, and thus help prevent future cases.
   It's important to keep the VAERS system working, and we can't do that without your help.
   We're asking that you report any significant adverse event that occurs after a vaccination,
   even if you're not sure that the vaccine caused it. It's easy to report by internet, phone,
   fax, or mail.
PHARMACOVIGILANCE AND RISK MANAGEMENT
  THROUGHOUT THE PRODUCT LIFECYCLE




 http://www.hc-sc.gc.ca/dhp-mps/homologation-licensing/develop/proglic_homprog_discus-eng.php
Progressive Licensing 2006


                                                     http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-
                                                     dgpsa/pdf/prodpharma/proglic_homprog_discus-eng.pdf




http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-
dgpsa/pdf/homologation-licensing/plfs_hpfd-eng.pdf
Progressive licensing
Presentation of Dr. Agnes Klein, Health
 Canada:
Health Canada Progressive Licensing - Professor Peivand Pirouzi
Health Canada Progressive Licensing - Professor Peivand Pirouzi
Health Canada Progressive Licensing - Professor Peivand Pirouzi
Health Canada Progressive Licensing - Professor Peivand Pirouzi
Health Canada Progressive Licensing - Professor Peivand Pirouzi
Health Canada Progressive Licensing - Professor Peivand Pirouzi
Health Canada Progressive Licensing - Professor Peivand Pirouzi
Health Canada Progressive Licensing - Professor Peivand Pirouzi
What is a Pharmacovigilance Plan?


 A plan proposed by a sponsor
  – for the ongoing evaluation of safety
    signals identified with the use of a product

  – to monitor at-risk populations which have
    not been adequately studied

 Plan may be developed at the time of product
  launch or after a signal is identified
What is a Pharmacovigilance Plan?


 A sponsor’s plan for an ongoing evaluation of safety
  signals*.
 May involve:
   – Expedited reporting of serious adverse events

   – Submission of adverse event report summaries at more frequent, pre-specified
     intervals

   – Implementation of active surveillance activities to identify adverse events that
     may or may not be reported through passive surveillance

   – Creation of registries or conducting patient/healthcare provider surveys

   – Conduct of Pharmacoepidemiologic studies using cohort study design


   * A safety signal is an apparent excess of adverse events associated with use
   of a product
Post market Requirements and
                Commitments
 Post market requirement and commitment studies and clinical trials
  occur after a drug or biological product has been approved by FDA.

 Guidance for Industry (PDF - 456KB) (Post market commitment-
  non-clinical). A separate Web site is available for post approval
  studies for medical devices.

 Website for Post market Requirements and Commitments
Database (FDA):
  http://www.accessdata.fda.gov/scripts/cder/pmc/index.cfm?StartRow
  =2&StepSize=1&Paging=Yes
The need

 Regulatory agencies are increasingly proactive in seeking out
  potential safety issues with marketed drugs

 Political and social pressures have increased along with faster
  communication channels

 Litigation due to the lack of Pharmacovigilance can be devastating
  for all concerned

 Failure to practice pharmacovigilance can lead to the suspension or
  withdrawal of license

Más contenido relacionado

La actualidad más candente

Argus Product Tab Screens - Katalyst HLS
Argus Product Tab Screens - Katalyst HLSArgus Product Tab Screens - Katalyst HLS
Argus Product Tab Screens - Katalyst HLSKatalyst HLS
 
Pharmacovigilance Process Work Flow - Katalyst HLS
Pharmacovigilance Process Work Flow - Katalyst HLSPharmacovigilance Process Work Flow - Katalyst HLS
Pharmacovigilance Process Work Flow - Katalyst HLSKatalyst HLS
 
Pharmacovigilance and Method of ADR reporting
Pharmacovigilance and Method of ADR reportingPharmacovigilance and Method of ADR reporting
Pharmacovigilance and Method of ADR reportingSMS MEDICAL COLLEGE
 
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCE
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCEAN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCE
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCERamakrishna K
 
Safety monitoring and reporting of adverse events of medical devices national...
Safety monitoring and reporting of adverse events of medical devices national...Safety monitoring and reporting of adverse events of medical devices national...
Safety monitoring and reporting of adverse events of medical devices national...Vivek Nayak
 
pharmacovigilance set up poster
pharmacovigilance set up posterpharmacovigilance set up poster
pharmacovigilance set up posterPriti Gupta
 
Presentation: Global pharmacovigilance networks - A regulator's
Presentation: Global pharmacovigilance networks - A regulator'sPresentation: Global pharmacovigilance networks - A regulator's
Presentation: Global pharmacovigilance networks - A regulator'sTGA Australia
 
ICSR Workflow & Management_Katalyst HLS
ICSR Workflow & Management_Katalyst HLSICSR Workflow & Management_Katalyst HLS
ICSR Workflow & Management_Katalyst HLSKatalyst HLS
 
Why Pharmacist is not allowed for Prescription drug, a thought
Why Pharmacist is not allowed for Prescription drug, a thoughtWhy Pharmacist is not allowed for Prescription drug, a thought
Why Pharmacist is not allowed for Prescription drug, a thoughtRajashri Survase Ojha
 
Argus Patient Screen Tab Training - Katalyst HLS
Argus Patient Screen Tab Training - Katalyst HLSArgus Patient Screen Tab Training - Katalyst HLS
Argus Patient Screen Tab Training - Katalyst HLSKatalyst HLS
 
Postmarket monitoring of therapeutic goods in Australia
Postmarket monitoring of therapeutic goods in AustraliaPostmarket monitoring of therapeutic goods in Australia
Postmarket monitoring of therapeutic goods in AustraliaTGA Australia
 
Fda adverse event reporting requirements for otc drugs
Fda adverse event reporting requirements for otc drugsFda adverse event reporting requirements for otc drugs
Fda adverse event reporting requirements for otc drugsComplianceOnline
 
Good Pharmacovigilance Practices
Good Pharmacovigilance Practices Good Pharmacovigilance Practices
Good Pharmacovigilance Practices sopi_1234
 
Pharmacovigilance ppt
Pharmacovigilance pptPharmacovigilance ppt
Pharmacovigilance pptPrasad Bhat
 
Argus Screen Shots General Tab - Katalyst HLS
Argus Screen Shots General Tab - Katalyst HLSArgus Screen Shots General Tab - Katalyst HLS
Argus Screen Shots General Tab - Katalyst HLSKatalyst HLS
 

La actualidad más candente (20)

Argus Product Tab Screens - Katalyst HLS
Argus Product Tab Screens - Katalyst HLSArgus Product Tab Screens - Katalyst HLS
Argus Product Tab Screens - Katalyst HLS
 
Pharmacovigilance Process Work Flow - Katalyst HLS
Pharmacovigilance Process Work Flow - Katalyst HLSPharmacovigilance Process Work Flow - Katalyst HLS
Pharmacovigilance Process Work Flow - Katalyst HLS
 
Pharmacovigilance and Method of ADR reporting
Pharmacovigilance and Method of ADR reportingPharmacovigilance and Method of ADR reporting
Pharmacovigilance and Method of ADR reporting
 
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCE
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCEAN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCE
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCE
 
Safety monitoring and reporting of adverse events of medical devices national...
Safety monitoring and reporting of adverse events of medical devices national...Safety monitoring and reporting of adverse events of medical devices national...
Safety monitoring and reporting of adverse events of medical devices national...
 
pharmacovigilance set up poster
pharmacovigilance set up posterpharmacovigilance set up poster
pharmacovigilance set up poster
 
Presentation: Global pharmacovigilance networks - A regulator's
Presentation: Global pharmacovigilance networks - A regulator'sPresentation: Global pharmacovigilance networks - A regulator's
Presentation: Global pharmacovigilance networks - A regulator's
 
Spontaneous reporting
Spontaneous reportingSpontaneous reporting
Spontaneous reporting
 
ICSR Workflow & Management_Katalyst HLS
ICSR Workflow & Management_Katalyst HLSICSR Workflow & Management_Katalyst HLS
ICSR Workflow & Management_Katalyst HLS
 
Drug Safety and Pharmacovigilance - Need for internationally harmonized pape...
Drug Safety and Pharmacovigilance  - Need for internationally harmonized pape...Drug Safety and Pharmacovigilance  - Need for internationally harmonized pape...
Drug Safety and Pharmacovigilance - Need for internationally harmonized pape...
 
Why Pharmacist is not allowed for Prescription drug, a thought
Why Pharmacist is not allowed for Prescription drug, a thoughtWhy Pharmacist is not allowed for Prescription drug, a thought
Why Pharmacist is not allowed for Prescription drug, a thought
 
Argus Patient Screen Tab Training - Katalyst HLS
Argus Patient Screen Tab Training - Katalyst HLSArgus Patient Screen Tab Training - Katalyst HLS
Argus Patient Screen Tab Training - Katalyst HLS
 
Postmarket monitoring of therapeutic goods in Australia
Postmarket monitoring of therapeutic goods in AustraliaPostmarket monitoring of therapeutic goods in Australia
Postmarket monitoring of therapeutic goods in Australia
 
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand PirouziICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
 
Fda adverse event reporting requirements for otc drugs
Fda adverse event reporting requirements for otc drugsFda adverse event reporting requirements for otc drugs
Fda adverse event reporting requirements for otc drugs
 
Good Pharmacovigilance Practices
Good Pharmacovigilance Practices Good Pharmacovigilance Practices
Good Pharmacovigilance Practices
 
Vaishali chadha
Vaishali chadhaVaishali chadha
Vaishali chadha
 
Pharmacovigilance ppt
Pharmacovigilance pptPharmacovigilance ppt
Pharmacovigilance ppt
 
Pv overview (2)
Pv overview (2)Pv overview (2)
Pv overview (2)
 
Argus Screen Shots General Tab - Katalyst HLS
Argus Screen Shots General Tab - Katalyst HLSArgus Screen Shots General Tab - Katalyst HLS
Argus Screen Shots General Tab - Katalyst HLS
 

Similar a Health Canada Progressive Licensing - Professor Peivand Pirouzi

Pharmacovigilance by bishnu koirala
Pharmacovigilance by bishnu koiralaPharmacovigilance by bishnu koirala
Pharmacovigilance by bishnu koiralaBishnu Koirala
 
Fda med watch
Fda med watchFda med watch
Fda med watchSridhar S
 
Understanding pharmacovigilance
Understanding pharmacovigilanceUnderstanding pharmacovigilance
Understanding pharmacovigilancefinenessinstitute
 
1591115199267_Pharmacovigilance.pptx
1591115199267_Pharmacovigilance.pptx1591115199267_Pharmacovigilance.pptx
1591115199267_Pharmacovigilance.pptxDrAniqaSundas
 
PHARMACOVIGILANCE - A Worldwide masterkey for Drug Monitoring
PHARMACOVIGILANCE - A Worldwide masterkey for Drug MonitoringPHARMACOVIGILANCE - A Worldwide masterkey for Drug Monitoring
PHARMACOVIGILANCE - A Worldwide masterkey for Drug MonitoringVenugopal N
 
Pharmacovigilance role and challenges phased by doctors
Pharmacovigilance role and challenges phased by doctorsPharmacovigilance role and challenges phased by doctors
Pharmacovigilance role and challenges phased by doctorsSneha Pandey
 
Interdisciplinary Education
Interdisciplinary EducationInterdisciplinary Education
Interdisciplinary EducationKate Loge
 
U.S. Food And Drug Administration
U.S. Food And Drug AdministrationU.S. Food And Drug Administration
U.S. Food And Drug AdministrationCarol
 
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,MizoramAn overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizorampougang golmei
 
Dispelling Common Misconceptions About Pharmacovigilance in 2023.docx
Dispelling Common Misconceptions About Pharmacovigilance in 2023.docxDispelling Common Misconceptions About Pharmacovigilance in 2023.docx
Dispelling Common Misconceptions About Pharmacovigilance in 2023.docxPharmamentors
 
TGA presentation: Postmarket Monitoring
TGA presentation: Postmarket MonitoringTGA presentation: Postmarket Monitoring
TGA presentation: Postmarket MonitoringTGA Australia
 
Patient centered Pharmacovigilance .. .
Patient centered Pharmacovigilance     .. .Patient centered Pharmacovigilance     .. .
Patient centered Pharmacovigilance .. .ClinosolIndia
 
Side effects of drugs products, medical devices & drugs healthcare data...
Side effects of drugs products, medical devices & drugs   healthcare data...Side effects of drugs products, medical devices & drugs   healthcare data...
Side effects of drugs products, medical devices & drugs healthcare data...PEPGRA Healthcare
 

Similar a Health Canada Progressive Licensing - Professor Peivand Pirouzi (20)

Pharmacovigilance by bishnu koirala
Pharmacovigilance by bishnu koiralaPharmacovigilance by bishnu koirala
Pharmacovigilance by bishnu koirala
 
Fda med watch
Fda med watchFda med watch
Fda med watch
 
Understanding pharmacovigilance
Understanding pharmacovigilanceUnderstanding pharmacovigilance
Understanding pharmacovigilance
 
Outlining pharmacovigilance
Outlining pharmacovigilanceOutlining pharmacovigilance
Outlining pharmacovigilance
 
1591115199267_Pharmacovigilance.pptx
1591115199267_Pharmacovigilance.pptx1591115199267_Pharmacovigilance.pptx
1591115199267_Pharmacovigilance.pptx
 
Pharmacovigilance and adr
Pharmacovigilance and adrPharmacovigilance and adr
Pharmacovigilance and adr
 
PHARMACOVIGILANCE - A Worldwide masterkey for Drug Monitoring
PHARMACOVIGILANCE - A Worldwide masterkey for Drug MonitoringPHARMACOVIGILANCE - A Worldwide masterkey for Drug Monitoring
PHARMACOVIGILANCE - A Worldwide masterkey for Drug Monitoring
 
Pharmacovigilance System
Pharmacovigilance SystemPharmacovigilance System
Pharmacovigilance System
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Data Speaks; What We Missed
Data Speaks; What We MissedData Speaks; What We Missed
Data Speaks; What We Missed
 
Pharmacovigilance role and challenges phased by doctors
Pharmacovigilance role and challenges phased by doctorsPharmacovigilance role and challenges phased by doctors
Pharmacovigilance role and challenges phased by doctors
 
Interdisciplinary Education
Interdisciplinary EducationInterdisciplinary Education
Interdisciplinary Education
 
U.S. Food And Drug Administration
U.S. Food And Drug AdministrationU.S. Food And Drug Administration
U.S. Food And Drug Administration
 
IQ Pharmacovigilance system (updated).pptx
IQ Pharmacovigilance system (updated).pptxIQ Pharmacovigilance system (updated).pptx
IQ Pharmacovigilance system (updated).pptx
 
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,MizoramAn overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
 
Dispelling Common Misconceptions About Pharmacovigilance in 2023.docx
Dispelling Common Misconceptions About Pharmacovigilance in 2023.docxDispelling Common Misconceptions About Pharmacovigilance in 2023.docx
Dispelling Common Misconceptions About Pharmacovigilance in 2023.docx
 
TGA presentation: Postmarket Monitoring
TGA presentation: Postmarket MonitoringTGA presentation: Postmarket Monitoring
TGA presentation: Postmarket Monitoring
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Patient centered Pharmacovigilance .. .
Patient centered Pharmacovigilance     .. .Patient centered Pharmacovigilance     .. .
Patient centered Pharmacovigilance .. .
 
Side effects of drugs products, medical devices & drugs healthcare data...
Side effects of drugs products, medical devices & drugs   healthcare data...Side effects of drugs products, medical devices & drugs   healthcare data...
Side effects of drugs products, medical devices & drugs healthcare data...
 

Más de Pharmaceutical Compliance Inspection unit, Crown College of Canada

Más de Pharmaceutical Compliance Inspection unit, Crown College of Canada (20)

Career competencies in Canada - Availablity and Flexibility Peivand Pirouzi P...
Career competencies in Canada - Availablity and Flexibility Peivand Pirouzi P...Career competencies in Canada - Availablity and Flexibility Peivand Pirouzi P...
Career competencies in Canada - Availablity and Flexibility Peivand Pirouzi P...
 
Career competencies in Canada - Communication Skills - Peivand Pirouzi, Ph.D.pdf
Career competencies in Canada - Communication Skills - Peivand Pirouzi, Ph.D.pdfCareer competencies in Canada - Communication Skills - Peivand Pirouzi, Ph.D.pdf
Career competencies in Canada - Communication Skills - Peivand Pirouzi, Ph.D.pdf
 
Creating Products and Pricing Strategies to meet customers needs - Peivand Pi...
Creating Products and Pricing Strategies to meet customers needs - Peivand Pi...Creating Products and Pricing Strategies to meet customers needs - Peivand Pi...
Creating Products and Pricing Strategies to meet customers needs - Peivand Pi...
 
Immigration and Citizenship Canada Funded Seminar on Education and Qualificat...
Immigration and Citizenship Canada Funded Seminar on Education and Qualificat...Immigration and Citizenship Canada Funded Seminar on Education and Qualificat...
Immigration and Citizenship Canada Funded Seminar on Education and Qualificat...
 
Immigration and Citizenship Funded Seminars: Professor Peivand Pirouzi - Care...
Immigration and Citizenship Funded Seminars: Professor Peivand Pirouzi - Care...Immigration and Citizenship Funded Seminars: Professor Peivand Pirouzi - Care...
Immigration and Citizenship Funded Seminars: Professor Peivand Pirouzi - Care...
 
Immigration and Citizenship - Prof. Peivand Pirouzi - career competencies in ...
Immigration and Citizenship - Prof. Peivand Pirouzi - career competencies in ...Immigration and Citizenship - Prof. Peivand Pirouzi - career competencies in ...
Immigration and Citizenship - Prof. Peivand Pirouzi - career competencies in ...
 
Immigration and citizenship funded seminar - Prof. Peivand Pirouzi - Mental H...
Immigration and citizenship funded seminar - Prof. Peivand Pirouzi - Mental H...Immigration and citizenship funded seminar - Prof. Peivand Pirouzi - Mental H...
Immigration and citizenship funded seminar - Prof. Peivand Pirouzi - Mental H...
 
Immigration and citizenship funded seminar - Prof. Peivand Pirouzi - Manageme...
Immigration and citizenship funded seminar - Prof. Peivand Pirouzi - Manageme...Immigration and citizenship funded seminar - Prof. Peivand Pirouzi - Manageme...
Immigration and citizenship funded seminar - Prof. Peivand Pirouzi - Manageme...
 
Immigration and citizenship funded seminar - Prof. Peivand Pirouzi - Entrepre...
Immigration and citizenship funded seminar - Prof. Peivand Pirouzi - Entrepre...Immigration and citizenship funded seminar - Prof. Peivand Pirouzi - Entrepre...
Immigration and citizenship funded seminar - Prof. Peivand Pirouzi - Entrepre...
 
Immigration and Citizenship Canada Funded Seminar on Education and Qualificat...
Immigration and Citizenship Canada Funded Seminar on Education and Qualificat...Immigration and Citizenship Canada Funded Seminar on Education and Qualificat...
Immigration and Citizenship Canada Funded Seminar on Education and Qualificat...
 
Immigration and Citizenship Canada Funded Seminar on Education and Qualificat...
Immigration and Citizenship Canada Funded Seminar on Education and Qualificat...Immigration and Citizenship Canada Funded Seminar on Education and Qualificat...
Immigration and Citizenship Canada Funded Seminar on Education and Qualificat...
 
Crown College of Canada - Your next step towards becoming faster qualified fo...
Crown College of Canada - Your next step towards becoming faster qualified fo...Crown College of Canada - Your next step towards becoming faster qualified fo...
Crown College of Canada - Your next step towards becoming faster qualified fo...
 
Immigration and Citizenship Canada Funded Seminar on Education and Qualificat...
Immigration and Citizenship Canada Funded Seminar on Education and Qualificat...Immigration and Citizenship Canada Funded Seminar on Education and Qualificat...
Immigration and Citizenship Canada Funded Seminar on Education and Qualificat...
 
Immigration and Citizenship Canada - Professor Peivand Pirouzi - Funded Progr...
Immigration and Citizenship Canada - Professor Peivand Pirouzi - Funded Progr...Immigration and Citizenship Canada - Professor Peivand Pirouzi - Funded Progr...
Immigration and Citizenship Canada - Professor Peivand Pirouzi - Funded Progr...
 
Health Canada - Prof. Peivand Pirouzi - Règlements de la Santé Canada pour l’...
Health Canada - Prof. Peivand Pirouzi - Règlements de la Santé Canada pour l’...Health Canada - Prof. Peivand Pirouzi - Règlements de la Santé Canada pour l’...
Health Canada - Prof. Peivand Pirouzi - Règlements de la Santé Canada pour l’...
 
Immigration and Citizenship Canada Funded Seminar on Education and Qualificat...
Immigration and Citizenship Canada Funded Seminar on Education and Qualificat...Immigration and Citizenship Canada Funded Seminar on Education and Qualificat...
Immigration and Citizenship Canada Funded Seminar on Education and Qualificat...
 
Immigration and Citizenship Canada - Professor Peivand Pirouzi - Funded Progr...
Immigration and Citizenship Canada - Professor Peivand Pirouzi - Funded Progr...Immigration and Citizenship Canada - Professor Peivand Pirouzi - Funded Progr...
Immigration and Citizenship Canada - Professor Peivand Pirouzi - Funded Progr...
 
Immigration and Citizenship Canada - Professor Peivand Pirouzi - Funded Progr...
Immigration and Citizenship Canada - Professor Peivand Pirouzi - Funded Progr...Immigration and Citizenship Canada - Professor Peivand Pirouzi - Funded Progr...
Immigration and Citizenship Canada - Professor Peivand Pirouzi - Funded Progr...
 
Immigration and Citizenship Canada - Professor Peivand Pirouzi - Funded Progr...
Immigration and Citizenship Canada - Professor Peivand Pirouzi - Funded Progr...Immigration and Citizenship Canada - Professor Peivand Pirouzi - Funded Progr...
Immigration and Citizenship Canada - Professor Peivand Pirouzi - Funded Progr...
 
Immigration and Citizenship Canada - Professor Peivand Pirouzi - Funded Progr...
Immigration and Citizenship Canada - Professor Peivand Pirouzi - Funded Progr...Immigration and Citizenship Canada - Professor Peivand Pirouzi - Funded Progr...
Immigration and Citizenship Canada - Professor Peivand Pirouzi - Funded Progr...
 

Último

MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 

Último (20)

MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 

Health Canada Progressive Licensing - Professor Peivand Pirouzi

  • 1. Post-Marketing Compliance & Health Canada Progressive Licensing Professor Peivand Pirouzi 2006 FDA/Health Canada Guidances
  • 2. Reporting Adverse Events for Drugs, Devices, Biologics and Dietary Supplements  FDA's Medwatch program allows health care professionals and consumers to report to the FDA serious problems with the medical products they prescribe, dispense, or use. These reports, along with follow-up investigations, can help to identify important safety concerns. Take the example of the antibiotic Zyvox. Within the first six months of Zyvox's marketing, FDA began getting MedWatch reports of myelosupression from clinicians who suspected that the drug might be responsible. After investigating the problem, we worked with the manufacturer to change the Zyvox labeling to warn about the potential for myelosuppression. Sometimes MedWatch reports highlight errors in prescribing or administering medications. For example, FDA received reports of patient injuries due to name confusion between LANOXIN, a heart medication, and what used to be called LEVOXINE, a thyroid medication. As a result, FDA asked the manufacturer to change the name of Levoxine, and now it's known as LEVOXYL, which is less likely to be confused with LANOXIN. The MedWatch system can also help detect problems with medical products other than drugs. For example, FDA received two reports of pneumococcal eye infections in patients who'd received corneal transplants. An FDA inspection identified numerous manufacturing problems, which led the company to recall the implants.
  • 3. Reporting Adverse Events for Drugs, Devices, Biologics and Dietary Supplements  Of course, MedWatch reports by themselves can not usually establish a causal relationship between an adverse event and a medical product - it may take a formal epidemiologic study to do that. Still, MedWatch reports are vital in making sure that medical products are safe, because they provide a rapid signal to FDA that problems may be occurring. It is important to keep the MedWatch system working, and we can not do that without your help. Here are the kinds of reports we need from you: • First of all, we are asking that you report any serious adverse event that might be associated with a drug, biologic, medical device, or dietary supplement. By "serious" we mean fatalities, hospitalizations, and medically significant events. We're especially interested in serious adverse events that aren't listed in the product labelling. • Secondly, report therapeutic failures - cases where the drug or device failed to work as it should. For example, let us know if a patient has to switch from one brand of a drug to another because the original one was ineffective. • Third, tell us about cases of use errors with medications or devices, including situations where the error may have been due to poor communication, or to ambiguities in product names, directions for use, or packaging. • And finally, we would like to know about product quality issues, such as suspected counterfeit products, defective components, potential contamination, device malfunctions and poor packaging.
  • 4. MedWatch: Reporting Adverse Events 1. FDA's Medwatch program allows health care professionals and consumers to report to the FDA serious problems with the medical products they prescribe, dispense, or use. These reports, along with follow-up investigations, can help to identify important safety concerns. 2. It is important to keep the MedWatch system working, and we can not do that without your help. Here are the kinds of reports we need from you: – Report any serious adverse event that might be associated with a drug, biologic, medical device, or dietary supplement. By "serious" we mean fatalities, hospitalizations, and medically significant events. FDA is especially interested in serious adverse events that aren't listed in the product labeling. – Report therapeutic failures - cases where the drug or device failed to work as it should (e.g., if a patient has to switch from one brand of a drug to another because the original one was ineffective). – Report cases of use errors with medications or devices, including situations where the error may have been due to poor communication, or to ambiguities in product names, directions for use, or packaging. – Report product quality issues, such as suspected counterfeit products, defective components, potential contamination, device malfunctions and poor packaging.
  • 5. Stronger Risk Management Program for Accutane (isotretinoin)  Isotretinoin is now a restricted distribution drug. This means that wholesalers won't be able to distribute the drug, pharmacists won't be able to dispense it, physicians won't be able to prescribe it, and patients won't be able to receive it unless they register. Doctors, patients, and pharmacies can obtain program information and register with iPLEDGE either online or by telephone at 1-866-495-0654. There is also a possible link between taking this drug and depression, suicidality, and psychosis. And for that reason, FDA has strengthened the labeling to help practitioners and patients identify and manage these risks. Any patient being treated with this drug should be carefully monitored for symptoms of depression, or suicidalility or psychosis. Patients should be told to stop the drug and contact their health professional if they experience any of these symptoms. Stopping the drug by itself, however, may not be sufficient. Psychiatric evaluation and intervention may be needed to prevent patients from harming themselves.
  • 6. Stronger Risk Management Program for Accutane (isotretinoin)  Revised October 28, 2005: The implementation dates of the iPLEDGE program have been revised. The date by which wholesalers and pharmacies must be registered /activated in IPLEDGE has been changed from November 1, 2005 to December 30, 2005. By March 1, 2006, only prescribers registered and activated in iPLEDGE can prescribe isotretinoin and only patients registered and qualified in iPLEDGE can be dispensed isotretinoin. Patients can begin registering and qualifying on December 30, 2005. FDA has developed stronger requirements to prevent fetal exposure to the drug Accutane (isotretinoin) along with its generic equivalents, such as Amnesteem, Sotret and Claravis. Isotretinoin is used to treat severe, recalcitrant, nodular acne, but it can cause serious birth defects if taken by pregnant women. These requirements are now going into effect in a new program called iPLEDGE. Under this program, wholesalers, prescribers, pharmacies and patients, both men and women, must register. Also, women who are capable of becoming pregnant must have two negative pregnancy tests before isotretinoin can be dispensed to them. They also must have a negative pregnancy test each month while taking the drug.
  • 7. FDA Studying Potential Safety Issues with Several Drugs  FDA has informed the health care community about ongoing safety reviews of several drugs. FDA is doing this as part of its commitment to inform health care professionals and the public about its ongoing drug safety reviews. Because this information is preliminary and there is scientific uncertainty, FDA is not taking regulatory action at this point, and is not advising health care professionals to stop using the drugs. FDA is continuing to evaluate the safety of these products, and will issue updates as more information becomes available. • CellCept (mycophenolate mofetil) and Myfortic (mycophenolic acid) • Singulair (montelukast) • Spiriva Handihaler (tiotropium) 
  • 8. New Rule Enhances the Safety of Human Cells and Tissues  FDA recently finalized a new rule that's designed to increase the safety of human cells, tissues and cellular and tissue-based products that are used for transplantation. The regulations apply to a broad range of products, including bone, ligaments, skin, corneas, and hematopoietic stem cells. They also apply to human heart valve and human dura mater allografts. The rule requires that manufacturers of these products recover, process, store, label, package and distribute them in a way that prevents the spread of communicable diseases. In this rule, FDA uses the word "manufacture" as an umbrella term to capture the many different actions an establishment might take in preparing these products for use. Many types of establishments may be involved in various steps from recovery, donor screening and testing, to storage and distribution. If an establishment is involved in any of the steps covered by the new regulation, FDA calls it a manufacturer. Prior to the new rule, there were some regulations in place to help assure the safety of human tissue. But the new rule covers a broader range of products and has more comprehensive requirements. This will help assure health care providers that the tissue and cellular products they use are the safest available.
  • 9. Reporting Adverse Events from Vaccines  Every year, tens of millions of vaccinations are given to children and adults in this country to prevent serious infectious diseases. FDA and CDC work together to monitor the safety of these vaccines using a registry known as Vaccine Adverse Event Reporting System, or VAERS. The VAERS registry contains reports of adverse events from patients, parents and health care providers, and it can help to identify important new vaccine safety concerns. Take the example of the rotavirus vaccine. During the first months after this vaccine was approved, epidemiologists at FDA and CDC noticed 15 VAERS reports of infants who had developed a particular type of intestinal obstruction after receiving the vaccine. The reports signaled a potential problem, which led to further investigations. As a result, the vaccination program was suspended, and then later, as investigations verified the serious risk, the manufacturer voluntarily removed the vaccine from the market.
  • 10. Reporting Adverse Events from Vaccines  Of course, it takes multiple reports and thorough investigation to confirm a causal relationship between an adverse event and a vaccine. Still, VAERS reports are on the front line in making sure that vaccines are safe, by providing a rapid signal that problems may be occurring. Sometimes VAERS reports highlight errors in prescribing or administering vaccines. For example, the VAERS registry was found to contain reports of 22 pregnant women who had received live virus varicella vaccine by mistake after being exposed to chickenpox. These women should have received a different product, varicella zoster immune globulin, or "VZIG." In this case, FDA and CDC worked with the varicella vaccine manufacturer to publish details about the 22 cases. By publishing this information, we were able to alert health care professionals of this potential mix-up, and thus help prevent future cases. It's important to keep the VAERS system working, and we can't do that without your help. We're asking that you report any significant adverse event that occurs after a vaccination, even if you're not sure that the vaccine caused it. It's easy to report by internet, phone, fax, or mail.
  • 11. PHARMACOVIGILANCE AND RISK MANAGEMENT THROUGHOUT THE PRODUCT LIFECYCLE http://www.hc-sc.gc.ca/dhp-mps/homologation-licensing/develop/proglic_homprog_discus-eng.php
  • 12. Progressive Licensing 2006 http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb- dgpsa/pdf/prodpharma/proglic_homprog_discus-eng.pdf http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb- dgpsa/pdf/homologation-licensing/plfs_hpfd-eng.pdf
  • 13. Progressive licensing Presentation of Dr. Agnes Klein, Health Canada:
  • 22. What is a Pharmacovigilance Plan?  A plan proposed by a sponsor – for the ongoing evaluation of safety signals identified with the use of a product – to monitor at-risk populations which have not been adequately studied  Plan may be developed at the time of product launch or after a signal is identified
  • 23. What is a Pharmacovigilance Plan?  A sponsor’s plan for an ongoing evaluation of safety signals*.  May involve: – Expedited reporting of serious adverse events – Submission of adverse event report summaries at more frequent, pre-specified intervals – Implementation of active surveillance activities to identify adverse events that may or may not be reported through passive surveillance – Creation of registries or conducting patient/healthcare provider surveys – Conduct of Pharmacoepidemiologic studies using cohort study design * A safety signal is an apparent excess of adverse events associated with use of a product
  • 24. Post market Requirements and Commitments  Post market requirement and commitment studies and clinical trials occur after a drug or biological product has been approved by FDA.  Guidance for Industry (PDF - 456KB) (Post market commitment- non-clinical). A separate Web site is available for post approval studies for medical devices.  Website for Post market Requirements and Commitments Database (FDA): http://www.accessdata.fda.gov/scripts/cder/pmc/index.cfm?StartRow =2&StepSize=1&Paging=Yes
  • 25. The need  Regulatory agencies are increasingly proactive in seeking out potential safety issues with marketed drugs  Political and social pressures have increased along with faster communication channels  Litigation due to the lack of Pharmacovigilance can be devastating for all concerned  Failure to practice pharmacovigilance can lead to the suspension or withdrawal of license